XM does not provide services to residents of the United States of America.
G
G

Gilead

News

U.S. Microstrategy, Snowflake, Target

U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target Nov 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Microstrategy, Snowflake and Target, on Thursday. HIGHLIGHTS * Dycom Industries Inc DY.N : D.A. Davidson raises target price to $220 from $210 * Microstrategy Inc MSTR.O : BTIG raises target price to $570 from $290 * Snowflake Inc SNOW.N : Piper Sandler raises target price to $185 from $165 * Target Corp TGT.
B
G
G
G
N
B
B
C
J
L

U.S. Airbnb, Post Holdings, Syndax Pharmaceuticals

U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals Nov 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, Post Holdings and Syndax Pharmaceuticals, on Monday. HIGHLIGHTS * Airbnb Inc ABNB.O : D.A. Davidson raises PT to $131 from $125 * Korro Bio Inc KRRO.O : Jonestrading initiates coverage with buy rating; PT $130 * Post Holdings Inc POST.N : JP Morgan raises target price to $135 from $125 *
A
A
B
E
G
H
S
D
D
E
E
A
C
C
D
I

Gilead’S Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy And Long-Term Safety Profile In Management Of Primary Biliary Cholangitis

BRIEF-Gilead’S Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy And Long-Term Safety Profile In Management Of Primary Biliary Cholangitis Nov 15 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD’S LIVDELZI (SELADELPAR) DEMONSTRATED A SUSTAINED EFFICACY AND LONG-TERM SAFETY PROFILE IN MANAGEMENT OF PRIMARY BILIARY CHOLANGITIS GILEAD SCIENCE
G

Gilead Files For Four-Part Senior Notes Offering Size Not Disclosed - SEC Filing

BRIEF-Gilead Files For Four-Part Senior Notes Offering Size Not Disclosed - SEC Filing Nov 13 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD FILES FOR FOUR-PART SENIOR NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: [ID:n0001104659-24-117332] Further company coverage: GILD.O
G

US FDA declines full approval for Intercept's liver disease drug

CORRECTED-UPDATE 2-US FDA declines full approval for Intercept's liver disease drug Corrects expert's title to "associate professor" from "assistant professor" in paragraph 8 of Nov 12 story By Bhanvi Satija and Puyaan Singh Nov 12 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, raising questions about its future in the market.
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.